[1] Schmidt VF, Dietrich O, Kazmierczak PM, et al. Optimized visualization of focal liver lesions and vascular structures in real-time T1-weighted gradient echo sequences for magnetic resonance-guided liver procedures. Diagn Interv Radiol, 2023, 29(1):128-137. [2] Leow KS, Kwok CY, Low HM, et al. Algorithm-based approach to focal liver lesions in contrast-enhanced ultrasound. Australas J Ultrasound Med, 2022, 25(3):142-153. [3] 吴旋音,田果,曹红翠,等.Sonazoid超声造影与增强磁共振成像对肝内局灶性病变的诊断价值比较.中华超声影像学杂志,2021,30(6):494-499. [4] Ruch B, Wagler J, Kumm K, et al. Hepatocellular carcinoma, alpha fetoprotein, and liver allocation for transplantation: past, present and future. Curr Oncol, 2022, 29(10):7537-7551. [5] Li G, Li N, Li S, et al. Expression and diagnostic value of abnormal prothrombin and osteopontin in hepatocellular carcinoma with cirrhosis. Am J Transl Re, 2024, 16(9):4688-4695. [6] 曹策,郁义星,王贝贝,等.增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨.实用肝脏病杂志,2019,22(6):896-899. [7] Möller K, Safai Zadeh E, Görg C, et al. Focal liver lesions other than hepatocellular carcinoma in cirrhosis: diagnostic challenges. J Transl Int Med, 2023, 10(4):308-327. [8] Dilek ON, Arslan Kahraman Dİ, Kahraman G. Carcinoembryonic antigen in the diagnosis, treatment, and follow-up of focal liver lesions. World J Gastrointest Surg, 2024, 16(4):999-1007. [9] Turco S, Tiyarattanachai T, Ebrahimkheil K, et al. Interpretable machine learning for characterization of focal liver lesions by contrast-enhanced ultrasound. IEEE Trans Ultrason Ferroelectr Freq Control, 2022, 69(5):1670-1681. [10] Fei X, Han P, Jiang B, et al. High frame rate contrast-enhanced ultrasound helps differentiate malignant and benign focal liver lesions. J Clin Transl Hepatol, 2022, 10(1):26-33. [11] 朱婷,张秋琴,车欣,等.超声造影定性及定量技术在鉴别肾脏良恶性肿瘤中的应用.中国临床研究,2020,33(12):1691-1693,1697. [12] Jeong WK, Kang HJ, Choi SH, et al. Diagnosing hepatocellular carcinoma using sonazoid contrast-enhanced ultrasonography: 2023 guidelines from the Korean society of radiology and the Korean society of abdominal eadiology. Korean J Radiol, 2023, 24(6):482-497. [13] Cao J, Wang H, Ruan X, et al. The American college of radiology contrast-enhanced ultrasound liver imaging reporting and data system and its modified version in diagnosing hepatocellular carcinoma via Sonazoid: a meta-analysis. Quant Imaging Med Surg, 2024, 14(7):4555-4566. [14] 王晶,张洁,赵静.超声造影联合声触诊组织量化技术鉴别肝血管瘤与肝细胞癌价值研究.实用肝脏病杂志,2022,25(4):575-578. [15] Chen Y, Zhu W, Yi Y, et al. Perfluorobutane (sonazoid) contrast-enhanced ultrasound to diagnose hepatocellular carcinoma: a systematic review and meta-analysis. Med Ultrason, 2024, 26(2):187-196. [16] Wang F, Numata K, Okada M, et al. Comparison of sonazoid contrast-enhanced ultrasound and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid MRI for the histological diagnosis of hepatocellular carcinoma. Quant Imaging Med Surg, 2021, 11(6):2521-2540. [17] Liu Q, Liu T, Liu X, et al. The efficacy of modified contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) using sonazoid in diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Quant Imaging Med Surg, 2024, 14(4):2927-2937. [18] Hwang JA, Jeong WK, Min JH, et al. Sonazoid-enhanced ultrasonography: comparison with CT/MRI Liver Imaging Reporting and Data System in patients with suspected hepatocellular carcinoma. Ultrasonography, 2021, 40(4):486-498. [19] 李晨,刘媛,许静涌,等.基于Kupffer细胞特异性摄取的超声造影在肝脏肿瘤性病变诊断中的应用价值.中华肝胆外科杂志,2020,26(12):907-911. [20] Kang HJ, Lee JM, Yoon JH, et al. SonazoidTM versus SonoVue© for diagnosing hepatocellular carcinoma using contrast-enhanced ultrasound in at-risk individuals: A prospective, single-center, intraindividual, noninferiority study. Korean J Radiol, 2022, 23(11):1067-1077. [21] 石磊,安梓铭,冯琴.联合检测血清AFP、AFP-L3%和PIVKA-Ⅱ水平早期诊断和判断原发性肝癌患者预后临床价值探讨.实用肝脏病杂志,2023,26(3):404-407. [22] Chan HLY, Vogel A, Berg T, et al. Performance evaluation of the elecsys PIVKA-II and elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open, 2022, 6(5):292-300. [23] Dopazo C, Søreide K, Rangelova E, et al. Hepatocellular carcinoma. Eur J Surg Oncol, 2024,50(1):107313. [24] Yang X, Yang C, Zhang S, et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell, 2024,42(2):180-197. [25] Peng Z, Fan W, Zhu B, et al.Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial (LAUNCH). J Clin Oncol, 2023,41(1):117-127. |